ESCMID eAcademy

ePosters are only viewable by those with a valid ECCMID 2021 registration.
If you already have a registration, please login to the online platform here.
If you are not yet registered, you can do so here.
Abstract
Discussion Forum (0)
Abstract number: 3305

Session Type: 1-hour Mini Oral Flash

Session Title: 1-hour Mini Oral Flash

Authors(s): G. Noberasco (1), D. Olobardi (1), E. Marcenaro (1), A. Battistini (2), B. Bruzzone (2), L. Sticchi (1, 2), F. Copello (3), P. Durando (1, 3), G. Icardi (1, 2), A. Orsi (1, 2)

Authors Affiliations(s): (1) Department of Health Sciences, University of Genoa, Italy, (2) Hygiene Unit, Ospedale Policlinico San Martino IRCCS, Italy, (3) Occupational Medicine Unit, Ospedale Policlinico San Martino IRCCS, Italy

Background:

In Italy the COVID-19 vaccination campaign started on 27th December 2020. Ospedale Policlinico San Martino IRCCS started the administration of the Pfizer-BioNTech COVID-19 vaccine among its healthcare workers the same day. A surveillance system was activated in order to monitor real-life vaccine effectiveness.

Methods:

We conducted a test-negative designed case-control study to estimate vaccine effectiveness (VE) of the Pfizer-BioNTech COVID-19 vaccine among healthcare workers. We considered real time PCR assay for the detection of SARS-CoV-2 in nasopharyngeal swab as valid test. Patients with a positive test for SARS-CoV-2 were classified as cases, while those with a negative test were classified as controls. VE was estimated by comparing positivity proportions between the vaccinated and unvaccinated patients. Patients were considered vaccinated 7 days after receiving the second dose of COVID-19 vaccine, patients were considered unvaccinated in absence of vaccination record or whether the test was collected prior to the 8th day after the completion of the vaccine schedule. Odds ratios (ORs) of having received COVID-19 vaccine for cases and controls were compared, with its 95% confidence intervals (CIs). We calculated VE as 1 minus the ORs multiplied by 100%.

Results:

We used data from 5646 nasopharyngeal swabs, which yielded 2883 patients and 238.2 patient-years of data. The mean length of the observational period was 30.2 days while the median was 19 (IQ 15-55) days. The mean age of our cohort was 43.8 years (median 47, IQR 31-55), 45.7 years (median 48, IQR 35-55) for the vaccinated group and 41.4 years (median 44, IQR 27.25-54) for the unvaccinated individuals (Figure 1). From the beginning of the vaccination campaign 125 healthcare workers tested positive for SARS-CoV-2 (mean age 43.4 years, median 46, IQR 30-54), 2 were vaccinated and 123 were unvaccinated. Among 2758 workers who tested negative, 1635 were vaccinated and 1123 not vaccinated. Vaccine effectiveness resulted 98.88% with a 95% confidence interval between 95.47% and 99.72% and a p level of significance of p<0.0001. The raw vaccine effectiveness of administrating only the first dose was 91.45% (95% CI 86.46%-94.61%, p<0.0001).

Conclusions:

Our preliminary data confirm that Pfizer-BioNTech COVID-19 vaccine is highly effective at preventing COVID-19 disease.

Keyword(s): COVID-19 vaccine, On-field effectiveness, Healthcare workers


COI Other: No conflict of interest
Abstract number: 3305

Session Type: 1-hour Mini Oral Flash

Session Title: 1-hour Mini Oral Flash

Authors(s): G. Noberasco (1), D. Olobardi (1), E. Marcenaro (1), A. Battistini (2), B. Bruzzone (2), L. Sticchi (1, 2), F. Copello (3), P. Durando (1, 3), G. Icardi (1, 2), A. Orsi (1, 2)

Authors Affiliations(s): (1) Department of Health Sciences, University of Genoa, Italy, (2) Hygiene Unit, Ospedale Policlinico San Martino IRCCS, Italy, (3) Occupational Medicine Unit, Ospedale Policlinico San Martino IRCCS, Italy

Background:

In Italy the COVID-19 vaccination campaign started on 27th December 2020. Ospedale Policlinico San Martino IRCCS started the administration of the Pfizer-BioNTech COVID-19 vaccine among its healthcare workers the same day. A surveillance system was activated in order to monitor real-life vaccine effectiveness.

Methods:

We conducted a test-negative designed case-control study to estimate vaccine effectiveness (VE) of the Pfizer-BioNTech COVID-19 vaccine among healthcare workers. We considered real time PCR assay for the detection of SARS-CoV-2 in nasopharyngeal swab as valid test. Patients with a positive test for SARS-CoV-2 were classified as cases, while those with a negative test were classified as controls. VE was estimated by comparing positivity proportions between the vaccinated and unvaccinated patients. Patients were considered vaccinated 7 days after receiving the second dose of COVID-19 vaccine, patients were considered unvaccinated in absence of vaccination record or whether the test was collected prior to the 8th day after the completion of the vaccine schedule. Odds ratios (ORs) of having received COVID-19 vaccine for cases and controls were compared, with its 95% confidence intervals (CIs). We calculated VE as 1 minus the ORs multiplied by 100%.

Results:

We used data from 5646 nasopharyngeal swabs, which yielded 2883 patients and 238.2 patient-years of data. The mean length of the observational period was 30.2 days while the median was 19 (IQ 15-55) days. The mean age of our cohort was 43.8 years (median 47, IQR 31-55), 45.7 years (median 48, IQR 35-55) for the vaccinated group and 41.4 years (median 44, IQR 27.25-54) for the unvaccinated individuals (Figure 1). From the beginning of the vaccination campaign 125 healthcare workers tested positive for SARS-CoV-2 (mean age 43.4 years, median 46, IQR 30-54), 2 were vaccinated and 123 were unvaccinated. Among 2758 workers who tested negative, 1635 were vaccinated and 1123 not vaccinated. Vaccine effectiveness resulted 98.88% with a 95% confidence interval between 95.47% and 99.72% and a p level of significance of p<0.0001. The raw vaccine effectiveness of administrating only the first dose was 91.45% (95% CI 86.46%-94.61%, p<0.0001).

Conclusions:

Our preliminary data confirm that Pfizer-BioNTech COVID-19 vaccine is highly effective at preventing COVID-19 disease.

Keyword(s): COVID-19 vaccine, On-field effectiveness, Healthcare workers


COI Other: No conflict of interest
First evidence of on-field effectiveness of Pfizer-BioNTech COVID-19 vaccine among healthcare workers of Ospedale Policlinico San Martino IRCCS, Genoa, Italy
Giovanni Noberasco
Giovanni Noberasco
ESCMID eAcademy. Noberasco G. 07/09/2021; 332761; 3305;
user
Giovanni Noberasco
Abstract
Discussion Forum (0)
Abstract number: 3305

Session Type: 1-hour Mini Oral Flash

Session Title: 1-hour Mini Oral Flash

Authors(s): G. Noberasco (1), D. Olobardi (1), E. Marcenaro (1), A. Battistini (2), B. Bruzzone (2), L. Sticchi (1, 2), F. Copello (3), P. Durando (1, 3), G. Icardi (1, 2), A. Orsi (1, 2)

Authors Affiliations(s): (1) Department of Health Sciences, University of Genoa, Italy, (2) Hygiene Unit, Ospedale Policlinico San Martino IRCCS, Italy, (3) Occupational Medicine Unit, Ospedale Policlinico San Martino IRCCS, Italy

Background:

In Italy the COVID-19 vaccination campaign started on 27th December 2020. Ospedale Policlinico San Martino IRCCS started the administration of the Pfizer-BioNTech COVID-19 vaccine among its healthcare workers the same day. A surveillance system was activated in order to monitor real-life vaccine effectiveness.

Methods:

We conducted a test-negative designed case-control study to estimate vaccine effectiveness (VE) of the Pfizer-BioNTech COVID-19 vaccine among healthcare workers. We considered real time PCR assay for the detection of SARS-CoV-2 in nasopharyngeal swab as valid test. Patients with a positive test for SARS-CoV-2 were classified as cases, while those with a negative test were classified as controls. VE was estimated by comparing positivity proportions between the vaccinated and unvaccinated patients. Patients were considered vaccinated 7 days after receiving the second dose of COVID-19 vaccine, patients were considered unvaccinated in absence of vaccination record or whether the test was collected prior to the 8th day after the completion of the vaccine schedule. Odds ratios (ORs) of having received COVID-19 vaccine for cases and controls were compared, with its 95% confidence intervals (CIs). We calculated VE as 1 minus the ORs multiplied by 100%.

Results:

We used data from 5646 nasopharyngeal swabs, which yielded 2883 patients and 238.2 patient-years of data. The mean length of the observational period was 30.2 days while the median was 19 (IQ 15-55) days. The mean age of our cohort was 43.8 years (median 47, IQR 31-55), 45.7 years (median 48, IQR 35-55) for the vaccinated group and 41.4 years (median 44, IQR 27.25-54) for the unvaccinated individuals (Figure 1). From the beginning of the vaccination campaign 125 healthcare workers tested positive for SARS-CoV-2 (mean age 43.4 years, median 46, IQR 30-54), 2 were vaccinated and 123 were unvaccinated. Among 2758 workers who tested negative, 1635 were vaccinated and 1123 not vaccinated. Vaccine effectiveness resulted 98.88% with a 95% confidence interval between 95.47% and 99.72% and a p level of significance of p<0.0001. The raw vaccine effectiveness of administrating only the first dose was 91.45% (95% CI 86.46%-94.61%, p<0.0001).

Conclusions:

Our preliminary data confirm that Pfizer-BioNTech COVID-19 vaccine is highly effective at preventing COVID-19 disease.

Keyword(s): COVID-19 vaccine, On-field effectiveness, Healthcare workers


COI Other: No conflict of interest
Abstract number: 3305

Session Type: 1-hour Mini Oral Flash

Session Title: 1-hour Mini Oral Flash

Authors(s): G. Noberasco (1), D. Olobardi (1), E. Marcenaro (1), A. Battistini (2), B. Bruzzone (2), L. Sticchi (1, 2), F. Copello (3), P. Durando (1, 3), G. Icardi (1, 2), A. Orsi (1, 2)

Authors Affiliations(s): (1) Department of Health Sciences, University of Genoa, Italy, (2) Hygiene Unit, Ospedale Policlinico San Martino IRCCS, Italy, (3) Occupational Medicine Unit, Ospedale Policlinico San Martino IRCCS, Italy

Background:

In Italy the COVID-19 vaccination campaign started on 27th December 2020. Ospedale Policlinico San Martino IRCCS started the administration of the Pfizer-BioNTech COVID-19 vaccine among its healthcare workers the same day. A surveillance system was activated in order to monitor real-life vaccine effectiveness.

Methods:

We conducted a test-negative designed case-control study to estimate vaccine effectiveness (VE) of the Pfizer-BioNTech COVID-19 vaccine among healthcare workers. We considered real time PCR assay for the detection of SARS-CoV-2 in nasopharyngeal swab as valid test. Patients with a positive test for SARS-CoV-2 were classified as cases, while those with a negative test were classified as controls. VE was estimated by comparing positivity proportions between the vaccinated and unvaccinated patients. Patients were considered vaccinated 7 days after receiving the second dose of COVID-19 vaccine, patients were considered unvaccinated in absence of vaccination record or whether the test was collected prior to the 8th day after the completion of the vaccine schedule. Odds ratios (ORs) of having received COVID-19 vaccine for cases and controls were compared, with its 95% confidence intervals (CIs). We calculated VE as 1 minus the ORs multiplied by 100%.

Results:

We used data from 5646 nasopharyngeal swabs, which yielded 2883 patients and 238.2 patient-years of data. The mean length of the observational period was 30.2 days while the median was 19 (IQ 15-55) days. The mean age of our cohort was 43.8 years (median 47, IQR 31-55), 45.7 years (median 48, IQR 35-55) for the vaccinated group and 41.4 years (median 44, IQR 27.25-54) for the unvaccinated individuals (Figure 1). From the beginning of the vaccination campaign 125 healthcare workers tested positive for SARS-CoV-2 (mean age 43.4 years, median 46, IQR 30-54), 2 were vaccinated and 123 were unvaccinated. Among 2758 workers who tested negative, 1635 were vaccinated and 1123 not vaccinated. Vaccine effectiveness resulted 98.88% with a 95% confidence interval between 95.47% and 99.72% and a p level of significance of p<0.0001. The raw vaccine effectiveness of administrating only the first dose was 91.45% (95% CI 86.46%-94.61%, p<0.0001).

Conclusions:

Our preliminary data confirm that Pfizer-BioNTech COVID-19 vaccine is highly effective at preventing COVID-19 disease.

Keyword(s): COVID-19 vaccine, On-field effectiveness, Healthcare workers


COI Other: No conflict of interest

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies